Zynerba Pharmaceuticals, Inc.
0M40.L
0M40.LZynerba Pharmaceuticals, Inc.
London Stock ExchangeReturn %
Stock
S&P500
1Y
104.55
34.93
3Y
-61.67
33.67
5Y
-76.89
94.66
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Mr. Armando Anido MBA
- Full Time Employees
- 25
- Sector
- Healthcare
- Industry
- Medical - Pharmaceuticals
- Address
- 80 West Lancaster Avenue Devon PA United States of America 19333
- IPO Date
- Jan 29, 2018
- Website
- zynerba.com
- Similar Companies
- Business
- Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. The company focuses on developing pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. It is developing Zygel, a pharmaceutically-produced cannabidiol formulated as a permeation-enhanced gel for transdermal delivery. The company was formerly known as AllTranz, Inc. and changed its name to Zynerba Pharmaceuticals, Inc. in August 2014. Zynerba Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Devon, Pennsylvania.